WeightRx review

Two things here pull in opposite directions and a reader should weigh both. The first is genuinely good: the price is on the homepage, the medication and the clinical care and the lab reviews are stated to be inside it, the compounder type is named in the terms rather than left vague, and there is a stated refund if the program produces no weight loss in thirty days. The second is the shape of the cheaper number. It is restated on the same page as a yearly figure and described twice in the questions and answers as a rate locked for a full term, and the terms of use confirm that shorter plans exist — monthly, three-month and six-month — without pricing any of them. So the advertised figure is what you pay each month if you commit for a year, and what you would pay without committing is not published. That is a real monthly rate on a condition rather than an annual dressed up as one, which is why it is quoted rather than refused, but the condition is the whole difference between this and a plan you can leave. The inversion between the two molecules is the more unusual fact. Nearly everywhere else that sells both, the dual agonist costs more, often substantially. Here it costs a third as much, and the comparison section pushes hard toward it, describing the single-pathway alternative as delivering appetite-focused results only. A reader who wants semaglutide should notice they are being quoted three times the price of the drug this seller would rather sell them, with no dose attached to either figure to explain the gap.

Vs median

$86/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not included

Labs

Optional

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

WeightRx dispenses through a 503A facility. Bloodwork is offered but not required. A clinician review is included in the price.

Two things here are worth a reader's attention and they pull in opposite directions. The first is genuinely good: the price is on the homepage, the medication and the clinical care and the labs are stated to be inside it, the compounder type is named in the terms rather than left vague, and there is a stated refund if the program does not work within thirty days. The second is the shape of the cheaper number. Eighty-three dollars is restated on the same page as a yearly figure and described twice in the FAQ as a rate locked for a full term, and the terms of use confirm that shorter plans exist — monthly, three-month and six-month — without pricing any of them. So the advertised figure is what you pay each month if you commit for a year, and what you would pay without committing is not published. That is a real monthly rate on a condition rather than an annual dressed up as one, which is why it is quoted here, but the condition is the whole difference between this and a plan you can leave. The inversion between the two molecules is the more unusual fact. Nearly everywhere else that sells both, the dual agonist costs more, often substantially. Here it costs a third as much, and the site's comparison section pushes hard toward it, describing the single-pathway alternative as delivering "appetite-focused results only" and "inconsistent energy". A reader who wants semaglutide should notice they are being quoted three times the price of the drug this seller would rather sell them, with no dose attached to either figure to explain the gap.

The cheaper figure is a term rate; the month-to-month plan its terms describe is unpriced.

• No dose sits behind either figure, so the gap between the two cannot be explained.
• The terms require binding arbitration and cap liability at a low fixed floor.

WeightRx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Microdosing tirzepatide
• Is compounded GLP-1 safe?
• The true annual cost of a plan
• What a flat price costs at a low dose